Publications

Legend

Tuberculosis and Non-tuberculous mycobacteria

Capability building

Gram-negative bacteria

April 18, 2024

17/04/24 ERA4TB – Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin

April 18, 2024

16/04/24 ERA4TB – A systematic review of economic evaluations of pharmacological treatments for active tuberculosis

November 15, 2023

PrIMAVeRa – Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review

November 1, 2023

PrIMAVeRa – Synthesizing pathogen- and infection-specific estimates of the burden of antimicrobial resistance in Europe for health-technology assessment: gaps, heterogeneity, and bias

October 11, 2023

ERA4TB – Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

October 4, 2023

PrIMAVeRa – A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe

April 21, 2023

ERA4TB – Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

April 13, 2023

UNITE4TB – Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

April 11, 2023

UNITE4TB – Tuberculosis: current challenges and beyond

February 16, 2023

PrIMAVeRa – Targeted mupirocin-based decolonization for Staphylococcus aureus carriers and the subsequent risk of mupirocin resistance in haemodialysis patients: a longitudinal study over 20 years

January 18, 2023

RespiriNTM – Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria

December 1, 2022

UNITE4TB – Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

November 15, 2022

ERA4TB – Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells

October 13, 2022

PrIMAVeRa – Estimating antimicrobial resistance burden in Europe: what are the next steps?

October 6, 2022

GNA NOW – Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species

September 8, 2022

COMBINE – Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

September 8, 2022

COMBINE – Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents

July 22, 2022

UNITE4TB – Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

March 21, 2022

UNITE4TB – Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

February 9, 2021

RespiriNTM & RespiriTB – Host-directed therapy to combat mycobacterial infections

November 24, 2020

ERA4TB – A lung-on-chip model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth

September 23, 2020

ERA4TB – Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions

August 5, 2020

COMBINE – Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections